Piqur Therapeutics is a clinical-stage pharmaceutical company focused on discovering and developing anti-cancer drugs that inhibit lipid kinase (PI3K) and mTOR. The company was incorporated in August 2011 as a spin-off of the University of Basel and is led by CEO Vladimir Cmiljanovic. Its lead compound, PQR309, has clinical activity and the company plans additional Phase 2 studies. Piqur also intends to advance preclinical safety work and initiate first clinical studies for a follow-up compound. The firm plans to use new funding to strengthen its operational base and support these clinical programs. Both PI3K and mTOR are described as clinically validated oncology targets.

Total raised

$19M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2015